Cargando…
Management and outcome of locally advanced oral squamous cell carcinoma
Management of locally advanced OSCC is multimodal. No single therapy has been proved to be efficacious. However there is a trend towards surgical intervention in operable disease. In this review we appraise the various therapies used for the management of locally advanced OSCC. We review the literat...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474551/ https://www.ncbi.nlm.nih.gov/pubmed/37661995 http://dx.doi.org/10.4103/njms.njms_125_22 |
_version_ | 1785100523305697280 |
---|---|
author | Bera, Rathindra N. Tandon, Sapna Singh, Akhilesh K. Boojar, Fargol M. A. Jaiswal, Gaurav Borse, Shraddha Pal, Uma S. Sharma, Naresh K. |
author_facet | Bera, Rathindra N. Tandon, Sapna Singh, Akhilesh K. Boojar, Fargol M. A. Jaiswal, Gaurav Borse, Shraddha Pal, Uma S. Sharma, Naresh K. |
author_sort | Bera, Rathindra N. |
collection | PubMed |
description | Management of locally advanced OSCC is multimodal. No single therapy has been proved to be efficacious. However there is a trend towards surgical intervention in operable disease. In this review we appraise the various therapies used for the management of locally advanced OSCC. We review the literature with regards to the various treatment options for locally advanced OSCC. We categorically divided the manuscript into resectable, unresectable and technically unresectable disease. Surgery is the ideal treatment modality for resectable disease. For unresectable disease concurrent chemoradiation appears to improve survival compared to radiotherapy alone. Induction therapy might downstage tumors in the unresectable category. Targeted and Immunotherapy is reserved for recurrent, metastatic or platinum refractory OSCC. Management of locally advanced OSCC is multimodal with surgery playing the primary role. In the event where the tumor is in operable concurrent chemoradiotherapy is regarded as the best treatment modality. Induction chemotherapy currently cannot be recommended for resectable or even unresectable oral squamous cell carcinomas. However for technically unresectable disease it might play a role in improving respectability but it depends on the response of the tumor. Targeted therapy and immunotherapy is currently used for recurrent, metastatic and/or platinum refractory Head and Neck cancers. Currently it is not recommended for initial management of locally advanced disease. |
format | Online Article Text |
id | pubmed-10474551 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-104745512023-09-03 Management and outcome of locally advanced oral squamous cell carcinoma Bera, Rathindra N. Tandon, Sapna Singh, Akhilesh K. Boojar, Fargol M. A. Jaiswal, Gaurav Borse, Shraddha Pal, Uma S. Sharma, Naresh K. Natl J Maxillofac Surg Review Article Management of locally advanced OSCC is multimodal. No single therapy has been proved to be efficacious. However there is a trend towards surgical intervention in operable disease. In this review we appraise the various therapies used for the management of locally advanced OSCC. We review the literature with regards to the various treatment options for locally advanced OSCC. We categorically divided the manuscript into resectable, unresectable and technically unresectable disease. Surgery is the ideal treatment modality for resectable disease. For unresectable disease concurrent chemoradiation appears to improve survival compared to radiotherapy alone. Induction therapy might downstage tumors in the unresectable category. Targeted and Immunotherapy is reserved for recurrent, metastatic or platinum refractory OSCC. Management of locally advanced OSCC is multimodal with surgery playing the primary role. In the event where the tumor is in operable concurrent chemoradiotherapy is regarded as the best treatment modality. Induction chemotherapy currently cannot be recommended for resectable or even unresectable oral squamous cell carcinomas. However for technically unresectable disease it might play a role in improving respectability but it depends on the response of the tumor. Targeted therapy and immunotherapy is currently used for recurrent, metastatic and/or platinum refractory Head and Neck cancers. Currently it is not recommended for initial management of locally advanced disease. Wolters Kluwer - Medknow 2023 2023-07-13 /pmc/articles/PMC10474551/ /pubmed/37661995 http://dx.doi.org/10.4103/njms.njms_125_22 Text en Copyright: © 2023 National Journal of Maxillofacial Surgery https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Review Article Bera, Rathindra N. Tandon, Sapna Singh, Akhilesh K. Boojar, Fargol M. A. Jaiswal, Gaurav Borse, Shraddha Pal, Uma S. Sharma, Naresh K. Management and outcome of locally advanced oral squamous cell carcinoma |
title | Management and outcome of locally advanced oral squamous cell carcinoma |
title_full | Management and outcome of locally advanced oral squamous cell carcinoma |
title_fullStr | Management and outcome of locally advanced oral squamous cell carcinoma |
title_full_unstemmed | Management and outcome of locally advanced oral squamous cell carcinoma |
title_short | Management and outcome of locally advanced oral squamous cell carcinoma |
title_sort | management and outcome of locally advanced oral squamous cell carcinoma |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474551/ https://www.ncbi.nlm.nih.gov/pubmed/37661995 http://dx.doi.org/10.4103/njms.njms_125_22 |
work_keys_str_mv | AT berarathindran managementandoutcomeoflocallyadvancedoralsquamouscellcarcinoma AT tandonsapna managementandoutcomeoflocallyadvancedoralsquamouscellcarcinoma AT singhakhileshk managementandoutcomeoflocallyadvancedoralsquamouscellcarcinoma AT boojarfargolma managementandoutcomeoflocallyadvancedoralsquamouscellcarcinoma AT jaiswalgaurav managementandoutcomeoflocallyadvancedoralsquamouscellcarcinoma AT borseshraddha managementandoutcomeoflocallyadvancedoralsquamouscellcarcinoma AT palumas managementandoutcomeoflocallyadvancedoralsquamouscellcarcinoma AT sharmanareshk managementandoutcomeoflocallyadvancedoralsquamouscellcarcinoma |